Daily Brief Health Care: HLB Life Science, Dentsply International, Esperion Therapeutics, Respiri Ltd and more

• On 21 March, HLB Life Science announced a rights offering capital raise worth 150 billion won. 
• The expected rights offering price is 13,630 won (32% lower than current price of 19,930 won)  and there are 11 million shares in this rights offering (10% of outstanding shares). 
• HLB Inc (028300 KS) is the largest controlling shareholder of HLB Life Science (067630 KS) with an 18.7% stake in the company.

• Dentsply International (XRAY US) guided for 2024 revenue of $3.96–4.02B, flat to up 1.5% on an organic basis and 12% growth in 2024 EPS at midpoint.
• The macro environment continues to be challenging. The company anticipates the ongoing softness in imaging will continue in 2024. Cost savings will support the bottom-line growth.
• In terms of every valuation metrics, Dentsply is overpriced compared to its U.S.-listed peers. Strong balance sheet, accelerating dividend, and buyback do not justify the pricey valuation.

• ESPR pharmaceutical company has two commercialized drugs and could potentially double in value with a $300 million milestone payout
• Ongoing litigation with DSE due to failure to meet payment obligations under a milestone agreement
• ESPR entitled to a Regulatory Milestone Payment pending regulatory approval for a licensed product in DSE territory, making it a strong investment opportunity with potential for high returns

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Edison Investment Research is terminating coverage on Respiri (RSH). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.